SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 30, 2003
-------------
Progenics Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware 000-23143 13-3379479
---------------------------- ---------- ----------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
777 Old Saw Mill River Road, Tarrytown, New York 10591
------------------------------------------------- ------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (914) 789-2800
--------------
------------------------------------------------------------
(Former name or former address, if changed since last report.)
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
EXHIBIT NUMBER DESCRIPTION
Exhibit 99.1 Press Release dated July 30, 2003 of
Progenics Pharmaceuticals, Inc. (the
"Company") announcing its results of
operations for the second quarter ended
June 30, 2003 and first half of 2003
(filed herewith).
Item 12. Results of Operations and Financial Condition.
On July 30, 2003, the Company issued a press release announcing its
results of operations for the second quarter ended June 30, 2003 and first half
of 2003. A copy of the press release is attached as Exhibit 99.1 to this report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
PROGENICS PHARMACEUTICALS, INC.
By: /s/ PHILIP K. YACHMETZ
-------------------------------------------------
Philip K. Yachmetz
Vice President, General Counsel and Secretary
Date: July 30, 2003